NSC 312887

Known as: NSC-312887 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1984-1990
012319841990

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1991
1991
Nineteen evaluable patients with advanced endometrial cancer refractory to one prior chemotherapeutic regimen were treated with a… (More)
Is this relevant?
1990
1990
Fludara I.V. (fludarabine phosphate) (2-F-ara-adenosine monophosphate [2-F-ara-AMP], NSC 312887) is the 5'-phosphate of 2-F-ara-A… (More)
Is this relevant?
1990
1990
This article presents data from the phase I and II clinical investigations of Fludara I.V. (fludarabine phosphate) (NSC 312887… (More)
Is this relevant?
1990
1990
Twenty evaluable patients with advanced cervical cancer refractory to one prior chemotherapy regimen were treated with a 5-day… (More)
Is this relevant?
1988
1988
A human tumor cloning system was utilized to screen for in vitro antitumor effects of the new purine antimetabolite 9-beta-D… (More)
Is this relevant?
1988
1988
Fourteen evaluable patients with advanced ovarian cancer refractory to one prior chemotherapy regimen were treated with a 5-day… (More)
Is this relevant?
1986
1986
Characterization of the pharmacokinetics of 2-FLAA has been completed in seven patients receiving 18 or 25 mg/m2 daily x5 of 2… (More)
  • table 1.2
  • table 2
  • figure 1
  • table 3
Is this relevant?
1984
1984
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887) is a new purine antimetabolite that has been evaluated in… (More)
Is this relevant?
1984
1984
9-beta-D-Arabinofuranosyl-2-fluoroadenine-5'-monophosphate (NSC 312887) (2-F-ara-AMP) is a new purine antimetabolite with… (More)
Is this relevant?